These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 15166192)

  • 21. Coronary heart disease in menopausal women: implications of primary and secondary prevention trials of hormones.
    Rossouw JE
    Maturitas; 2005 May; 51(1):51-63. PubMed ID: 15883110
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevention of cardiovascular events in early menopause: a possible role for hormone replacement therapy.
    Antonicelli R; Olivieri F; Morichi V; Urbani E; Mais V
    Int J Cardiol; 2008 Nov; 130(2):140-6. PubMed ID: 18617278
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hormone therapy and cardiovascular disease--still much to be learnt.
    Mikkola TS; Ylikorkala O
    Gynecol Endocrinol; 2005 Feb; 20(2):116-20. PubMed ID: 15823832
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease.
    Prentice RL; Langer RD; Stefanick ML; Howard BV; Pettinger M; Anderson GL; Barad D; Curb JD; Kotchen J; Kuller L; Limacher M; Wactawski-Wende J;
    Am J Epidemiol; 2006 Apr; 163(7):589-99. PubMed ID: 16484450
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The bioidentical hormone debate: are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than commonly used synthetic versions in hormone replacement therapy?
    Holtorf K
    Postgrad Med; 2009 Jan; 121(1):73-85. PubMed ID: 19179815
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estrogen for heart disease: risk or benefit?
    Harv Womens Health Watch; 2000 Jun; 7(10):1-2. PubMed ID: 10810060
    [No Abstract]   [Full Text] [Related]  

  • 27. Current evidence about the effect of hormone replacement therapy on the incidence of major conditions in postmenopausal women.
    Beral V; Reeves G; Banks E
    BJOG; 2005 Jun; 112(6):692-5. PubMed ID: 15924521
    [No Abstract]   [Full Text] [Related]  

  • 28. Re: "invited commentary: Hormone therapy and risk of coronary heart disease-why renew the focus on the early years of menopause?".
    Rosenberg L
    Am J Epidemiol; 2007 Dec; 166(12):1480-1; author reply 1481-2. PubMed ID: 17993654
    [No Abstract]   [Full Text] [Related]  

  • 29. Re: "invited commentary: Hormone therapy and risk of coronary heart disease--why renew the focus on the early years of menopause?".
    Dören M; Greiser EM
    Am J Epidemiol; 2007 Dec; 166(12):1479-80; author reply 1481-2. PubMed ID: 17977898
    [No Abstract]   [Full Text] [Related]  

  • 30. Cardiovascular risk and hormone replacement therapy.
    Lawlor DA; Smith GD
    Curr Opin Obstet Gynecol; 2006 Dec; 18(6):658-65. PubMed ID: 17099339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The latest elaboration of the Women's Health Initiative data on hormone replacement therapy and cardiovascular disease in postmenopausal women.
    Genazzani AR; Gambacciani M; Simoncini T
    Gynecol Endocrinol; 2007 Apr; 23(4):183-5. PubMed ID: 17505935
    [No Abstract]   [Full Text] [Related]  

  • 32. Hormone replacement therapy and cardiovascular disease: increased risks of venous thromboembolism and stroke, and no protection from coronary heart disease.
    Lowe GD
    J Intern Med; 2004 Nov; 256(5):361-74. PubMed ID: 15485471
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Commentary: hormone replacement therapy and coronary heart disease: four lessons.
    Petitti D
    Int J Epidemiol; 2004 Jun; 33(3):461-3. PubMed ID: 15166191
    [No Abstract]   [Full Text] [Related]  

  • 34. Hormone therapy and selective estrogen receptor modulators for prevention of coronary heart disease in postmenopausal women estrogen replacement from the cardiologist's perspective.
    Mobasseri S; Liebson PR; Klein LW
    Cardiol Rev; 2004; 12(6):287-98. PubMed ID: 15476565
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effects of SERM on breast cancer and cardiovascular disease: making a comparison between raloxifene use and hormone replacement therapy on the risks of the diseases].
    Higuchi T; Mizunuma H
    Clin Calcium; 2004 Oct; 14(10):81-4. PubMed ID: 15577136
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hormone replacement therapy and the cardiovascular system lessons learned and unanswered questions.
    Ouyang P; Michos ED; Karas RH
    J Am Coll Cardiol; 2006 May; 47(9):1741-53. PubMed ID: 16682298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Observational studies and clinical trials of menopausal hormone therapy: can they both be right?
    Allison MA; Manson JE
    Menopause; 2006; 13(1):1-3. PubMed ID: 16607089
    [No Abstract]   [Full Text] [Related]  

  • 38. ITT for observational data: worst of both worlds?
    Stampfer MJ
    Epidemiology; 2008 Nov; 19(6):783-4; discussion 789-93. PubMed ID: 18813017
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The story of the reversal of opinion about hormone replacement therapy and cardiovascular disease].
    Løkkegaard EC
    Ugeskr Laeger; 2005 Mar; 167(10):1166-70. PubMed ID: 15810574
    [No Abstract]   [Full Text] [Related]  

  • 40. [Hormones and ischemic cardiopathy in women: here it starts again!].
    Panico S
    Epidemiol Prev; 2002; 26(6):273-5. PubMed ID: 12619488
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.